G007-LK: Specific Tankyrase 1/2 Inhibitor for Wnt/β-Catenin and Cancer Research

Executive Summary: G007-LK is a small-molecule inhibitor with high specificity for tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), showing IC50 values of 46 nM and 25 nM, respectively, for auto-poly(ADP ribosyl)ation inhibition in vitro (APExBIO). It effectively suppresses Wnt/β-catenin signaling in Wnt3a-induced HEK 293 cell models, with an ST-Luc reporter IC50 of 0.05 μM. In APC-mutant colorectal cancer models, G007-LK induces β-catenin degradation and AXIN1/2 stabilization, leading to tumor growth suppression in vivo (Jia et al., 2017). In hepatocellular carcinoma (HCC) cells, G007-LK downregulates YAP/TAZ signaling by stabilizing AMOTL1/2 proteins. The compound is highly soluble in DMSO (≥26.5 mg/mL), but insoluble in water or ethanol, and should be stored at -20°C as a solid for stability (APExBIO).

Biological Rationale

Tankyrases (TNKS1 and TNKS2) are poly(ADP-ribose) polymerases (PARPs) involved in regulating critical cellular processes, including Wnt/β-catenin signaling, telomere maintenance, and cell cycle progression (Jia et al., 2017). Dysregulation of tankyrase activity is implicated in oncogenesis, particularly in colorectal cancer and HCC, where tankyrase levels are elevated and drive aberrant cell proliferation. Inhibition of tankyrases disrupts β-catenin stabilization and nuclear translocation, thereby attenuating Wnt-driven transcriptional programs in cancers with APC mutations (adrenorphin.net). Additionally, tankyrase-mediated degradation of angiomotin proteins leads to YAP activation, linking tankyrase activity with Hippo pathway regulation.

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK is a selective inhibitor that binds to the catalytic PARP domain of TNKS1 and TNKS2, blocking auto-poly(ADP-ribosyl)ation. This inhibition prevents tankyrase-mediated degradation of AXIN1/2, leading to stabilization of the β-catenin destruction complex. As a result, cytosolic and nuclear β-catenin levels decrease, reducing Wnt target gene expression. In APC-mutant colorectal cancer cells, G007-LK induces formation of degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin, promoting β-catenin proteasomal degradation (APExBIO). In HCC models, G007-LK stabilizes AMOTL1/2, which are negative regulators of YAP/TAZ, thereby inhibiting the Hippo pathway effector YAP (Jia et al., 2017).

Evidence & Benchmarks

• G007-LK inhibits TNKS1/2 auto-poly(ADP-ribosyl)ation with in vitro IC50 values of 46 nM (TNKS1) and 25 nM (TNKS2) (APExBIO).
• In Wnt3a-stimulated HEK 293 cells, G007-LK suppresses ST-Luc Wnt reporter activity with an IC50 of 0.05 μM (APExBIO).
• In SW480 APC-mutant colorectal cancer cells, G007-LK induces β-catenin degradasome formation, reducing cytosolic and nuclear β-catenin levels (adrenorphin.net).
• In COLO-320DM xenograft mouse models, G007-LK suppresses tumor growth and reduces TNKS1/2 and β-catenin protein levels, while stabilizing AXIN1/2 (bi10773.com).
• In human HCC cell lines, G007-LK decreases YAP protein levels and YAP/TEAD reporter activity, concomitant with upregulation of AMOTL1/2 proteins (Jia et al., 2017).
• Synergistic inhibition of HCC cell proliferation is observed when G007-LK is combined with MEK or AKT inhibitors (Jia et al., 2017).

This article extends the mechanistic and translational context provided in "Redefining Wnt/β-Catenin and Hippo Pathway Intervention" by focusing on recent, peer-reviewed quantitative benchmarks and practical research integration. For a concise analysis of optimal applications in cancer biology, see "G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β...", which this article updates with the latest in vivo evidence. For detailed molecular action and product usage, consult the APExBIO G007-LK tankyrase 1/2 inhibitor page.

Applications, Limits & Misconceptions

G007-LK is primarily employed to interrogate tankyrase function, Wnt/β-catenin signaling, Hippo pathway modulation, and oncogenic signaling in APC-mutant colorectal cancer and HCC research. Its ability to induce β-catenin degradation and stabilize AXIN1/2 makes it a preferred tool in studies requiring precise pathway inhibition. In vivo, it enables pharmacologic suppression of tumor growth and modulation of β-catenin and YAP-driven transcriptional programs. However, its use is limited to preclinical and laboratory research; no clinical approvals exist for therapeutic applications.

Common Pitfalls or Misconceptions

• G007-LK does not function as a broad-spectrum PARP inhibitor; it is highly specific for tankyrase 1/2 and does not inhibit PARP1/2 at relevant concentrations (APExBIO).
• It is not water- or ethanol-soluble; improper solvent use can result in precipitation and loss of activity.
• Long-term storage of DMSO solutions is not recommended due to compound instability; always store as a solid at -20°C.
• G007-LK is intended for research use only and lacks regulatory approval for any therapeutic indication.
• Inhibition of Wnt/β-catenin signaling by G007-LK is context-dependent and may require functional AXIN/β-catenin pathway components.

Workflow Integration & Parameters

For most cell-based assays, G007-LK can be dissolved in DMSO (≥26.5 mg/mL) and diluted into culture media; a brief warming to 37°C or ultrasonic bath can enhance dissolution (APExBIO). The recommended storage is as a solid at -20°C. Use within 2 weeks of solution preparation for optimal reproducibility. Concentration ranges for in vitro studies typically span 0.01–10 μM, depending on the cell type and assay. In vivo dosing requires solubilization in appropriate vehicles (e.g., PEG400/DMSO mixtures) and should be referenced from peer-reviewed protocols (Jia et al., 2017).

Conclusion & Outlook

G007-LK is a validated, potent, and selective tankyrase 1/2 inhibitor enabling precise dissection of the Wnt/β-catenin and Hippo pathways in cancer research. Its mechanisms of β-catenin degradation and AXIN1/2 stabilization, coupled with downregulation of YAP signaling, position it at the forefront of APC mutation colorectal cancer and HCC model studies. While not a therapeutic agent, G007-LK provides a robust research platform for exploring tankyrase biology and developing next-generation pathway inhibitors. For validated formulations, protocols, and product availability, see the APExBIO G007-LK product page (B5830 kit).